IMR Press / FBL / Volume 14 / Issue 9 / DOI: 10.2741/3453

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Somatostatin receptor expression in thymic tumors
Show Less
1 Department of Endocrinology and Medical Sciences and Center of Excellence for Biomedical Research, University of Genova, viale Benedetto XV, 6, Genova
2 Medical Oncology, n.3 Naples Local Health Unit, “S.Giovanni di Dio” Hospital, Frattamaggiore, Naples, Italy
3 Unit of Pathology, National Cancer Institute “Fondazione G. Pascale”, via M. Semmola, Naples
4 Department of Internal Medicine, Section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
5 Department of Molecular and Clinical Endocrinology & Oncology, University “Federico II”, Naples
6 Casa di Cura “Villa Maria”, Mirabella Eclano, Avellino, Italy
Front. Biosci. (Landmark Ed) 2009, 14(9), 3304–3309;
Published: 1 January 2009

Detection of thymic tumors by (111In-DTPA0)octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)2A and sst3 expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant (111In-DTPA0)octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4- to 6-fold). By IHC, 4 tumors were positive for sst2A and sst3; two for sst2A and five tumors for sst3. Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst2A was confined to malignant epithelial cells or within stromal structures, and sst3 was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.

Back to top